FDA Approved: OTEZLA — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA announces that Amgen's supplemental application for OTEZLA (apremilast) has been approved, updating the product labeling accordingly.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Disease
• Plaque Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• OTEZLA (apremilast)

Snippet

SUPPL AP for OTEZLA (APREMILAST)